Kathalene Keller Riney, NP
Family · Evansville, INNPI 1457786642
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $340,829 of the $382,546 with a category attached, or 89.1%. AbbVie accounts for 90.8% of it on its own, with 47 other manufacturers making up the rest. Among family clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,205 payments — averaging $317.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$348K
- Phathom Pharmaceuticals, Inc.$25K
- Amgen$1K
- AstraZeneca$1K
- Novo Nordisk$812
- E.r. Squibb & Sons, L.L.C.$687
- plus $6K from 42 others
What the payments were for
- Consulting fees$1,3400%
- Speaking & faculty fees$340,82989%
- Travel & lodging$21,7656%
- Food & beverage$18,2095%
- Education$4030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$281,116
- UBRELVY$54,711
- VOQUEZNA$24,439
- QULIPTA$12,681
- AIRSUPRA$495
- FARXIGA$260
- BREZTRI$260
- myRisk$196
- Austedo XR$125
- TRELEGY ELLIPTA$123
- Auvelity$117
- DEXCOM G6 TRANSMITTER$113
How this compares
$382,546 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 58 | $117,305 |
| VraylarCariprazine Hcl | 40 | $55,478 |
| FarxigaDapagliflozin Propanediol | 34 | $42,719 |
| MounjaroTirzepatide | 31 | $39,603 |
| JardianceEmpagliflozin | 25 | $26,888 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $17,960 |
| EliquisApixaban | 17 | $16,619 |
| LinzessLinaclotide | 11 | $14,251 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 15 | $4,733 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 14 | $3,160 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $2,607 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 41 | $1,665 |
| Pantoprazole Sodium | 110 | $1,448 |
| SynthroidLevothyroxine Sodium | 13 | $1,412 |
| Duloxetine Hcl | 69 | $1,175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $812 | $117,30558 claims |
| AbbVieVraylar, Linzess, Synthroid | $347,541 | $71,14164 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,048 | $60,67948 claims |
| Lilly USA, LLCMounjaro | $506 | $39,60331 claims |
| Boehringer IngelheimJardiance | $80 | $26,88825 claims |
| PfizerEliquis | $329 | $16,61917 claims |
| GSKArexvy, Shingrix | $593 | $7,89329 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.
Other family in Evansville
- Lacey MatheisEvansville$139K
- Elizabeth JohnsonEvansville$108K
- Erica ThomasonEvansville$14K
- Tina SizemoreIndianapolis$888K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Myra SikwataHobart$131K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.